MAP4K3 and non-small cell lung carcinoma: Clinically, GLK overexpression predicts poor overall and progression-free survival in non-small-cell lung carcinoma (NSCLC) [86], though the mechanisms through which GLK contributes to disease pathogenesis are not clear at this time.